REGN-COV2 antibodies to be trialled in RECOVERY Trials in UK

United Kingdom // 15 September, 2020

The world’s largest trial of potential treatments for COVID-19, the Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial, will begin investigating REGN-COV2. REGN-COV2 is a cocktail of monoclonal antibodies, developed by US biotech company Regeneron, to specifically target the SARS-CoV-2 virus. At least 2,000 patients will receive REGN-COV2 in the phase 3 open labelled trial, along with standard of care.

REGN-COV2 is already under investigation in the United States as a COVID-19 treatment.

LATEST NEWS

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
Webinars

Pandemic Information Webinars
(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars